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ABSTRACT 
The myoblast-mediated delivery of angiogenic genes represents a cell-based approach for 
targeted induction of therapeutic collateralization. Here, we tested the superiority of myoblast-
mediated co-delivery of vascular endothelial growth factor-A (VEGF) together with platelet-
derived growth factor-BB (PDGF-BB) on transpial collateralization of an indirect 
encephalomyosynangiosis (EMS) in a model of chronic cerebral ischemia. Mouse myoblasts 
expressing a reporter gene alone (empty vector; EV), VEGF, PDGF-BB or VEGF and PDGF-BB 
through a single bi-cistronic vector (VIP) were implanted into the temporalis muscle of an EMS 
following permanent ipsilateral internal carotid artery occlusion in adult, male C57BL/6N mice. 
Over 84 days, myoblast engraftment and gene product expression, hemodynamic impairment, 
transpial collateralization, angiogenesis, pericyte recruitment and post-ischemic neuroprotection 
were assessed. By day 42, animals that received PDGF-BB in combination with VEGF (VIP) 
showed superior hemodynamic recovery, EMS collateralization and ischemic protection with 
improved pericyte recruitment around the parenchymal vessels and EMS collaterals. Also, 
supplementation of PDGF-BB resulted in a striking astrocytic activation with intrinsic VEGF 
mobilization in the cortex below the EMS. Our findings suggest that EMS surgery together with 
myoblast-mediated co-delivery of VEGF/PDGF-BB may have the potential to serve as a novel 
treatment strategy for augmentation of collateral flow in the chronically hypoperfused brain.
Key words Collateral circulation; Gene therapy; Moyamoya disease; Neurosurgery; 
Revascularization
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INTRODUCTION
Patients with chronic cerebral hemodynamic impairment due to progressive stenosis or occlusion 
of major cerebral arteries carry a risk of recurrent transient ischemic attacks and cerebral 
infarction up to 20-30% at 2 years.1,2 Direct extra- to intracranial bypass grafting with 
augmentation of collateral flow was expected to reduce this risk of subsequent ischemic stroke 
but surprisingly failed to show a benefit compared to best medical management, most likely due 
to the high procedure-related perioperative stroke rate up to 15% within the first 30 days following 
surgery.1,3 An encephalomyosynangiosis (EMS), represents a simple and safe alternative to 
direct bypass surgery for treatment of chronic cerebral hemodynamic impairment and describes 
a technique, where a vascularized pedicle graft of the temporalis muscle is placed in direct contact 
with the surface of the hypoperfused brain after removal of the bone and dura.4,5 However, 
hemodynamic rescue following the spontaneous formation of transpial extra- to intracranial 
collaterals between the muscle / brain interface of an EMS is not immediate and appears to be 
effective only in pediatric patients with Moyamoya vasculopathy and high endogenous pro-
angiogeinic activity6-10 and not in adults with hemodynamic compromise due to arteriosclerotic 
cerebrovascular disease.11,12 Importantly, effective collateralization through an EMS not only 
requires remodeling and outgrowth of pre-formed collateral vessels – arteriogenesis in the 
classical sense – but also de novo growth and maturation of an entirely new vascular network 
following mechanisms of postnatal vasculo- and angiogenesis, which precede the formation of 
patent and functional collaterals between the extracranial and intracranial vascular beds. 
Here, Vascular Endothelial Growth Factor-A (VEGF) delivered at an appropriate 
microenvironmental concentration was shown to act as a key regulator of formation and 
maintenance of the native collateral density in the brain, next to the role of VEGF as a factor to 
induce capillary arterialization and proliferation of preformed arteriolar-arterial vessel networks.13-
18 However, VEGF delivery alone may act as a negative regulator of vessel maturation,19 which 
is determined by pericyte recruitment mainly controlled by platelet-derived growth factor-BB 
(PDGF-BB).20,21 Against this background, we previously showed that a balanced, myoblast-
mediated co-expression of VEGF and PDGF-BB using a single bi-cistronic vector, VIP, appears 
to provide superior conditions to harness the potency of VEGF for safe and effective induction of 
therapeutic neovascularization.22-25 Together with an EMS, retroviraly transfected myoblasts 
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appear to be the ideal drug delivery vehicle for targeted and specific stimulation of collateral 
vessel growth in chronic cerebral ischemia, based on their capacity to fuse with pre-existing host 
muscle fibers of the EMS and ensure a highly localized gene product delivery without the need 
for immune suppression or the propensity to proliferate in an uncontrolled manner.17,18,23,25-29 
To overcome the limitations of VEGF single-factor delivery, we therefore tested the 
efficacy of a balanced, myoblast-mediated co-expression of both murine VEGF (VEGF164) and 
human PDGF-BB (hPDGF-BB) on collateralization and ischemic protection in a mouse model of 
EMS revascularization and chronic cerebral ischemia.
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MATERIAL AND METHODS
Ethics Statement
Experiments were permitted by the local ethics committee on animal research (Landesamt für 
Gesundheit und Soziales, Berlin, Germany. LAGeSO No. G 0186/16) and in conformity with the 
German Law for Animal Protection and the National Institute of Health Guidelines for Care and 
Use of Laboratory Animals. Experiments have been reported following the ARRIVE guidelines.
Cell culture and growth factor secretion
The isolation, cultivation and retroviral infection of primary C57BL/6 mouse myoblasts was 
performed as previously described.23,25,27,30 Briefly, primary myoblasts were transduced with a 
constitutive LacZ-encoding retrovirus to express the β-galactosidase marker gene (Empty Vector 
[EV]). In addition, LacZ-encoded myoblasts were further transduced with retroviral vectors 
expressing murine VEGF164 (designated VEGF), hPDGF-BB (designated PDGF), or both at a 
fixed ratio to each other from a bi-cistronic cassette through the encephalomyocarditis virus 
Internal Ribosomal Entry Site (IRES) (designated VIP for VEGF-IRES-PDGF) as previously 
described.23 A truncated version of CD8a was co-expressed with VEGF164 or hPDGF-BB from a 
similar bi-cistronic construct (VEGF- and PDGF-myoblasts) or from a separate promoter (VIP) as 
a cell surface marker of transduced cells. Early-passage myoblast clones were randomly isolated 
using a FacStar cell sorter (Becton Dickinson, San Jose, CA, USA) and single-cell isolation was 
confirmed visually. All myoblast populations were cultured in 5% CO2 on collagen coated dishes. 
For optimal selection of myoblast populations based on previous functional and 
morphological results,23 VEGF164 and hPDGF-BB secretion was quantified in cell culture 
supernatants using specific ELISA kits (R&D Systems, Abingdon, UK) as described 
previously.17,23 Myoblast populations were selected for implantation as follows: monoclonal VEGF 
myoblasts homogeneously secreting 61.0±2.9ng/106 cells/day of VEGF164, polyclonal PDGF-
myoblasts secreting on average 45.7±2.4ng/106 cells/day of hPDGF-BB and polyclonal VIP-
myoblasts secreting an average amount of 58.9±5.8ng/106 cells/day of VEGF164 and 
9.7±0.7ng/106 cells/day of hPDGF-BB at a fixed ratio in each cell.
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Animals and design
A total number of 292 male C57BL/6N mice (Charles River WIGA GmbH, Sulzfeld, Germany), 
aged 10-12 weeks were randomized to the following experimental groups:
 EV: ICA-O and EMS with implantation of empty vector myoblasts
 VEGF: ICA-O and EMS with implantation of VEGF164-expressing myoblasts
 PDGF: ICA-O and EMS with implantation of hPDGF-BB-expressing myoblasts
 VIP: ICA-O and EMS with implantation of VEGF164- and hPDGF-BB co-expressing myoblasts
Animals were randomized with the help of an online randomizing tool 
(https://www.randomizer.org). Along the course of the observation period up to 84 days, 44 
animals were excluded due to procedure-related mortality (EV n = 12, VEGF n = 13, PDGF n = 
11, VIP n = 8). For all procedures, mice were anesthetized with 70 mg/kg ketamine and 16 mg/kg 
xylazine, and body temperature was maintained at 37°C. Ketamine and xylazine were selected 
based on our previous model validation31 in order to minimize cardiovascular and respiratory 
effects on cerebral blood flow (CBF) that may occur with volatile anesthetics, opioids or 
benzodiazepines and hamper reliable assessment of the acetazolamide-specific cerebrovascular 
reserve capacity (CVRC). Mice were kept in an enriched environment with free access to food 
and water. Blinding for treatment and data analysis was ensured by coding the myoblasts before 
implantation. To determine group allocation, un-coding was performed after individual data 
analysis.
ICA-occlusion, encephalomyosynangiosis and myoblast implantation 
The internal carotid artery occlusion (ICA-O) was performed immediately before the EMS 
procedure at a time point defined as day 0. For ICA-O, the animal was positioned supine and the 
right-sided ICA was permanently ligated with an 8/0 silk suture. Next, the animal was turned to 
prone position and a right-sided craniectomy was performed along the superior temporal line to 
the temporal scull base, extending from the bregma to the lambdoid suture using a diamond-tip 
micro drill (Proxxon GmbH, Wartberg/Aist, Austria). The dura was completely excised along the 
margin of the craniectomy. To secure the temporal muscle above the cortical surface after 
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myoblast implantation (see below), the overlying muscle fascia was sutured to the contralateral 
aponeurosis and the skin was readapted with 6/0 Nylon as previously described.28,29,31 For 
implantation, cultured EV-, VEGF-, PDGF- and VIP-myoblasts were trypsinized and re-
suspended in phosphate-buffered saline with 0.5% bovine serum albumin. Five cell suspensions 
of 5µL, each containing 5×105 myoblasts (equaling a total number of 25x105 cells) were implanted 
into the temporalis muscle using a Hamilton® microsyringe with a 26-gauge needle (Hamilton Co., 
Reno, NV, USA) during the EMS procedure on day 0.
Measurement of cerebral hemodynamics using Laser Speckle Imaging
Resting CBF and acetazolamide-specific CVRC of the affected (right) hemisphere was 
determined on days 0, 7, 21, 42 and 84 with non-invasive laser speckle imaging (LSI).  After 
positioning of the laser speckle device (MoorFLPI, Moor Instruments, Devon, England), a five-
minute baseline measurement of cortical resting perfusion (CBF-Flux measured in arbitrary 
perfusion units) was recorded within a 6x4 mm region of interest over the right middle cerebral 
artery (MCA) territory, which permitted a combined arterial, venous and parenchymal perfusion 
and blood flow assessment. A 120-second CBF-Flux plateau was calculated as baseline 
perfusion. Next, 50mg/kg acetazolamide (Diamox, Goldshield Pharmaceuticals Ltd., Surrey, 
England) was injected intraperitoneally and the acetazolamide-specific cerebrovascular reserve 
capacity (CVRC) was calculated as the percent perfusion change between the baseline plateau 
and a 120-second CBF-Flux plateau after a maximum rise in CBF-Flux.29,31 (days 0-21: EV n=21, 
VEGF n=20, PDGF n=22, VIP n=23; day 42: EV n=17, VEGF n=15, PDGF n=17, VIP n=16; day 
84: EV n=8, VEGF n=8, PDGF n=8, VIP n=9). The normalized resting perfusion at each time point 
(defined as 100%) and mean CVRC on day 0 was additionally determined in the unaffected (left) 
hemisphere.
Middle cerebral artery occlusion and cortical stroke volume assessment
The percentage of ipsilateral cortical infarction after 60-minute MCA-O and 6-hour reperfusion 
was assessed through magnetic resonance imaging (MRI) on days 21, 42 and 84. For temporary 
MCA-occlusion (MCA-O), animals were turned to supine position and the midline neck incision 
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was reopened. The carotid sheath was carefully dissected and the right ICA was incised distal to 
the site of the previous ICA-O. Next, a 7/0 silicone-rubber coated monofilament (Doccol 
monofilament, length 20mm, diameter with coating 0.21±0.01mm; Doccol cooperation, Sharon, 
MA, USA) was smoothly inserted up to the level of the ICA/MCA bifurcation. After 60 minutes, the 
filament was removed and the ICA was permanently ligated proximal to the incision. Six hours 
later, the volume of the ischemic cortical tissue and of the total cortex ipsilateral to the 
encephalomyosynangiosis (EMS) was determined in a 7-tesla animal MRI (Bruker Pharmascan 
70/16 with a 20mm radio frequency volume resonator, Bruker Biospin, Ettlingen, Germany) and 
analyzed with purpose-designed biomedical imaging software (Analyze 10.0, Biomedical Imaging 
Resource, Mayo Clinic, Rochester, MN, USA) to determine the percentage of cortical infarction 
according to signal hyperintensity in serial T2-weighted coronal images.29 Laser Speckle Imaging 
was used to visualize the cortical perfusion pattern over the affected hemisphere during the 60-
minute occlusion. Correlation between the percentage of cortical infarction and CVRC was 
analyzed to assess the effect of the hemodynamic response following EMS and VIP-myoblast 
implantation. (day 21: EV n=5, VEGF n=6, PDGF n=6, VIP n=6; day 42: EV n=7, VEGF n=6, 
PDGF n=7, VIP n=7; day 84: EV n=6, VEGF n=8, PDGF n=5, VIP n=7).
FITC-lectin perfusion for assessment of transpial collaterals
To determine transpial collateralization across the EMS, an in-vivo Fluorescein isothiocyanate 
(FITC)-lectin perfusion was performed via the external carotid artery ipsilateral to the side of the 
EMS in two groups of animals with and without MCA-O (please see above). The ipsilateral 
external carotid artery was cannulated with a polyethylene catheter (inner diameter 0.28mm; outer 
diameter 0.61mm) connected to a micro syringe. The ipsilateral common carotid artery was 
proximally ligated and a solution of 50µl (100µg) FITC-lycopersicon esculentum (tomato) lectin 
(Vector Laboratories Inc., Burlingame, CA, USA) and 200µl phosphate-buffered saline was 
injected. The mice were decapitated within 2 seconds after the injection and whole-head 
specimens were snap-frozen at minus 80°C. To characterize the positive or negative 
development of transpial collaterals we defined the EMS take-rate parameter: In each section, 
transpial collateralization was determined positive only after direct visual confirmation of (a) 
continuous FITC-lectin positive vessels crossing from the muscle into the cortex and (b) a distinct 
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association of these vessels with the resident vasculature of the cortical region below the EMS. 
The total number of sections with positive transpial collaterals was counted in each animal and 
the individual EMS take-rate was defined positive if collaterals were noted in ≥50% of all section 
levels. The overall take-rate was calculated as the percentage of positive versus negative EMS’. 
Further, Correlation between the number of collaterals and CVRC was analyzed to assess the 
effect of transpial collateralization on the hemodynamic response. (day 21: EV n=5, VEGF n=6, 
PDGF n=6, VIP n=6; day 42: EV n=7; VEGF n=7, PDGF n=7, VIP n=7; day 84: EV n=6, VEGF 
n=8, PDGF n=6, VIP n=7).
Immunohistochemistry
To assess fusion and reporter gene expression of implanted myoblasts at the muscle / brain 
interface of the EMS, an X-gal stain was performed on day 21 after implantation and is described 
elsewhere in detail.28 Briefly, 60μm coronal cryosections of snap-frozen, whole-head specimens 
were fixed with 4% paraformaldehyde, rinsed in phosphate buffered saline and incubated with X-
gal reaction buffer (diluted 40mg/ml X-gal in dimethlformamide to 1:40 with X-gal dilution buffer) 
for 24 hours. Myoblast fusion and reporter gene expression was identified according to the visual 
confirmation of -gal positive cells.
For analysis of transpial collaterals and neuron survival after MCA-O, vessel density and 
pericyte coverage, proliferation and neuronal apoptosis, and astrocyte activation with VEGF or 
phospho-PDGF-Rβ co-localization, 10 µm coronal cryosections of snap-frozen, whole-head 
specimens were obtained from the anterior, middle and posterior region of the EMS (Bregma -
0.5mm, -1.5mm and -2.5mm, respectively). Sections were mounted and visualized under a 
fluorescence-enhanced microscope (Axio Imager 2, Zeiss, Oberkochem, Germany). For analysis 
of pericyte recruitment of transpial collaterals, 20µm cryosections were obtained in animals that 
underwent FITC-lection perfusion without MCA-O and visualized under a laser-scanning 
microscope (LSM710, Zeiss, Oberkochem, Germany). Negative control information was obtained 
by incubating tissue samples with only the corresponding secondary antibodies.
 To determine surviving neurons following MCA-O together with patent transpial 
collaterals, NeuN positive cells per mm2 (days 21, 42 and 84) and FITC-lectin positive collaterals 
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per animal (day 42) were counted in the cortical region below and across the muscle / brain 
interface of the EMS (day 21: EV n=5, VEGF n=6, PDGF n=6, VIP n=6; day 42: EV n=7; VEGF 
n=7, PDGF n=7, VIP n=7; day 84: EV n=6, VEGF n=8, PDGF n=6, VIP n=7). To assess the 
morphology of transpial collaterals (EV n=7, VEGF n=7, PDGF n=7, VIP n=7) and the cortical 
vasculature (EV n=4, VEGF n=4, PDGF n=4, VIP n=4) on day 42, the vessel density and pericyte 
coverage were evaluated by a combined CD31/Desmin stain. Vessel density within the cortical 
area below the EMS was calculated as CD31-positive vessels per mm2 for vessels below and 
above 10µm in diameter. Pericyte coverage for the cortical vessels and transpial collaterals was 
expressed as the percentage of CD31-positive vessels with Desmin co-localization. Neuronal 
apoptosis on day 42 (EV n=4, VEGF n=4, PDGF n=4, VIP n=4) in the cortical region below the 
EMS was assessed by a combined TUNEL/NeuN stain. Apoptotic neurons were calculated as 
cells per mm2 (Supplemental Figure I). Astrocyte activation and VEGF or phospho-PDGF-Rβ co-
localization in relationship to the cortical vasculature below the EMS on day 42 (EV n=4, VEGF 
n=4, PDGF n=4, VIP n=4) were detected by a combined glial fibrillary acidic protein (GFAP) / 
VEGF or phospho-PDGF-Rβ / CD31 stain. GFAP / VEGF or phospho-PDGF-Rβ co-localization 
was calculated as surface area (µm2) per mm2 or pPDGF-Rβ coverage (%) of the GFAP-positive 
surface area, respectively.
Surviving neurons were detected using mouse monoclonal anti-mouse NeuN (5µg/ml, 
Millipore, Darmstadt, Germany) detected by Dylight 649-conjugated goat anti-mouse IgG 
antibody (1.25µg/ml, BioLegend, San Diego, CA, USA). Vessel density and pericyte coverage 
were evaluated by a rat anti-mouse CD31 (0.31µg/ml, BD Biosciences, Franklin Lakes, NJ, USA) 
detected by Cy3-conjugated donkey anti-rat IgG antibody (7.5µg/ml, Jackson ImmunoResearch 
Laboratories, West Grove, PA, USA) and a rabbit anti-mouse Desmin (10µg/ml, Abcam, 
Cambridge, UK) detected by Dylight 649-conjugated donkey anti-rabbit IgG antibody (1.25µg/ml, 
BioLegend, San Diego, CA, USA). Neuronal apoptosis in the cortical region below the EMS was 
evaluated by TUNEL (Apoptosis detection kit, CHEMICON International Inc., Merck Life Science, 
Darmstadt, Germany) and NeuN co-localization. For assessment of astrocyte and VEGF co-
localization in the cortical region below the EMS, glial fibrillary acidic protein (GFAP) was identified 
by a polyclonal chicken anti-GFAP (21.6µg/ml, Abcam, Cambridge, UK) detected by Fluorescein-
conjugated goat anti-chicken IgY antibody (5µg/ml, Abcam, Cambridge, UK). The VEGF 
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expression on responsive astrocytes was visualized by a rabbit anti-VEGFA (10µg/ml, Abcam, 
Cambridge, UK) detected by Cy3-conjugated anti-rabbit IgG antibody (5µg/ml, Abcam, 
Cambridge, UK). The expression of phospho-PDGF-Rβ was visualized by a rabbit anti-
phosphoY740 PDGF-Rβ (10µg/ml, Abcam, Cambridge, UK) detected by Cy3-conjugated donkey 
anti-rabbit IgG antibody (7.5µg/ml, Jackson ImmunoResearch Laboratories, West Grove, PA, 
USA).
Real-time PCR and Western blot
For analysis of exogenous (IRES) gene product transcription and VEGF / hPDGF-BB protein 
expression in the temporalis muscle and within the muscle / brain interface of the EMS on day 
42, tissue samples of the temporalis muscle and the interface were harvested and snap-frozen 
for real-time PCR (rtPCR) and Western blot analysis (EV n=4, VEGF n=4, PDGF n=4, VIP n=4). 
For transcription analysis, RNA isolation was performed with Trizol, according to standard 
Trizol extraction protocol (Invitrogen, Carlsbad, CA, USA). The amount of RNA was quantified 
using Infinite 200 PRO (TECAN, Männedorf, Switzerland). cDNA was reversely transcribed using 
QuantiTec Reverse Transcription Kit (Qiagen, Venlo, Netherlands) according to the 
manufacturer’s recommendation. Real-time PCR amplifications were performed in triplicates in a 
25μL reaction volume using the SYBR Premix Ex Taq Kit (Takara Bio Inc., Shiga, Japan) with the 
indicated primer pairs of IRES-forward: GCTCTCCTCAAGCGTATTCAACA and IRES-reverse: 
CCCCAGATCAGATCCCATACA and a 7900HT Fast rtPCR System or ABI Prism 7000 Sequence 
Detection System (Applied Biosystems, Foster City, CA, USA). For standardization, GAPDH was 
used as housekeeping gene (GAPDH-forward: GGCCTTCCGTGTTCCTACC; GAPDH-reverse: 
AACCTGGTCCTCAGTGTACC). All data were analyzed by the relative quantification method 
(ΔΔCt). For Western blot, samples harvested from the temporalis muscle or the muscle / brain 
interface were homogenized with a solution of RIPA buffer and Protease inhibitors (ratio 
Sample:RIPA = 1:10). For Western blot analysis, the protein concentration of each sample was 
determined using a Pierce BCA Protein Assay Kit (Thermo Fisher Scientific, Waltham, MA, USA) 
according to the standard protocol. Samples containing 100μg of protein were subjected to 10% 
polyacrylamide gel electrophoresis in the presence of 0.1% sodium dodecyl sulfate. Protein bands 
were transferred from the gel to PVDF membranes, which were incubated with a 1:1000 dilution 
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of rabbit polyclonal anti-VEGFA antibody (1µg/ml, Abcam AB46154, Cambridge, UK) or with 
1:100 dilution of rabbit polyclonal anti-platelet-derived growth factor (PDGF) antibody (1µg/ml, 
Abcam AB16829, Cambridge, UK) and membranes were reacted with horseradish peroxidase-
conjugated donkey anti-rabbit IgG antibody (Jackson ImmunoResearch Laboratories, West 
Grove, PA, USA). Protein bands on membranes were detected by an enhanced 
chemiluminescence method. Quantification of the Western Blot bands was performed after 
normalization of the GAPDH densities. First, images were converted to 8bit grayscale and 
identical threshold intensity settings were applied with the help of image processing and analysis 
software (ImageJ, Ver. 2.0.0-rc-68/1.52g, https://imagej.nih.gov/ij/). Next, we determined the 
background-subtracted densities (Integrated Density) of the protein of interest (PI; VEGF or 
PDGF-BB) and the normalizing control (GAPDH) bands. For each PI, we then identified the 
GAPDH band with the highest density (Control, VEGF, PDGF or VIP). In order to obtain a 
normalized GAPDH value, we then divided all GAPDH density values by the highest GAPDH 
density value. To then quantify the density of the PI in each lane based on the normalized GAPDH 
value, each PI density was divided by the normalized GAPDH value in their respective lane.
Statistical analysis
Data are presented as mean ± standard deviation (SD) or percentage. All continuous variables 
passed normality and equal variance testing, determined by the Shapiro-Wilks and F-Test and 
parametric testing was performed accordingly. Baseline perfusion and CVRC were compared by 
a two-way ANOVA for repeated measurements with subsequent pair-wise comparison of means 
by Fisher’s least projected difference test. Cortical infarct size, NeuN positive cells after MCA-O, 
transpial collaterals, EMS take rate, vessel density, pericyte coverages, neuronal apoptosis and 
GFAP/VEGF or phospho-PDGF-Rβ co-localization were compared by a one-way ANOVA 
procedure with Bonferroni correction for multiple comparisons. Relative quantity (ΔΔCt) using 
IRES primer in real-time PCR was compared by a non-parametric Kruskal-Wallis test with Dunn’s 
post hoc analysis for multiple comparisons. For correlation of “Cortical infarction” versus “CVRC” 
and “Number of collaterals” versus “CVRC”, a Spearman correlation analysis was used due to 
failed normality tests. Statistics were performed with GraphPad Prism for Mac (Version 5.0f, 
GraphPad Software, San Diego, California, USA). Statistical significance was set at p<0.05.
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RESULTS
Myoblast engraftment and gene product expression
On day 21, X-gal staining revealed successfully fused hybrid myofibers in all experimental groups 
(Figure 1A). A blush extracellular -gal signal as a sign of local reporter gene expression by non-
fused myoblasts without fiber structure was noted particularly after implantation of PGDF 
myoblasts. In the temporalis muscle, rtPCR using IRES primer on day 42 confirmed the 
exogenous transcription of VEGF164 and/or hPDGF-BB in VEGF-, PDGF- and VIP-myoblasts, 
respectively, with the highest transcription rate noted in PDGF myoblasts. An increased amount 
of total VEGF and/or hPDGF-BB in the temporalis muscle following implantation of VEGF-, 
PDGF- or VIP myoblasts was confirmed by Western blot (Figure 1B).
Hemodynamic rescue following VEGF164 and hPDGF-BB co-delivery
Laser Speckle Images of typical resting perfusion and cortical blood flow responses to 
acetazolamide on day 42 are illustrated in Figure 2 and expressed as percentage compared to 
contralateral (resting perfusion) or overall percentage (CVRC). First, we analyzed resting 
(baseline) perfusion between treatment groups. On day 0 following ICA-O with EMS and myoblast 
implantation, resting perfusion over the affected hemisphere was reduced >20% and comparable 
between groups. Although none of the groups reached resting perfusion levels of the contralateral 
hemisphere, animals treated with VIP myoblasts showed signs of a sustained perfusion increase 
over time (Figure 2A and 2B, upper panel). We then focused on the cortical perfusion response 
after acetazolamide challenge: Compared to the hemodynamic response over the unaffected 
hemisphere on day 0, CVRC over the affected hemisphere on day 0 was reduced >50% and 
comparable between groups. Over time, spontaneous hemodynamic rescue occurred in all 
groups with the earliest and most pronounced CVRC recovery in VIP-treated animals, followed 
by animals treated with VEGF-myoblasts (Figure 2A and 2B, lower panel).
Cortical stroke and regional perfusion following MCA-O
At day 42, animals treated with VIP myoblasts had a 30-35% reduction of cortical infarction 
compared to animals treated with PDGF or EV myoblasts. At day 84, this benefit for VIP-
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compared to EV-treated animals was sustained, corresponding to a 38% reduction of cortical T2 
signal hyperintensity. Laser Speckle Imaging confirmed sustained cortical perfusion during the 
MCA-occlusion period in VIP-treated animals compared to animals that only received EV 
myoblasts. A significant negative correlation was found between the percentage of cortical 
infarction and the degree of hemodynamic impairment (*p = 0.016; r = -0.59) (Figure 3). 
Neuroprotection after MCA-O and transpial collateralization
Following proximal stroke through MCA-O at day 21, 42 and 84, VIP-treated animals had a 
significantly higher number of surviving neurons in the cortical region below the EMS than animals 
treated with EV myoblasts alone (Figure 4A and 4B). On day 42, positive spontaneous transpial 
collateralization was detected in all groups with an 85% increase in patent extra- to intracranial 
collaterals and the highest EMS take-rate in VIP-treated animals compared to animals that 
received EV myoblasts (Figure 4C). The functional hemodynamic relevance of this improved 
collateralization is suggested by a significant correlation of the number of collaterals to the CVRC 
(**p=0.0076; r = 0.29), next to the 20% greater relative CVRC difference in animals with 10 or 
more collaterals (Figure 4D).
Vessel density, pericyte recruitment and neuronal apoptosis
At day 42, treatment with VIP and PDGF myoblasts resulted in a significant 50% increase in the 
density of cortical vessels >10µm compared to animals that only received EV myoblasts, which 
was paralleled by a 13-15% increase in pericyte coverage of vessels <10µm, indicating an 
increased microvascular maturation (Figure 5A and 5B). Regarding the morphology of transpial 
collaterals, however, only VIP-treated animals consistently showed a dense mural Desmin 
coverage of the FITC-positive extra- to intracranial collaterals crossing from the muscle into the 
brain (Figure 5C and 5D). Further, TUNEL staining on day 42 revealed an 85% reduction of 
apoptotic neurons following treatment with VIP compared to EV myoblasts (Supplemental Figure 
I).
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PDGF-BB dependent astrocyte activation with intrinsic VEGF mobilization
In addition to its role in stimulating vessel growth and maturation, VEGF and PDGF-BB are 
important neurotrophic factors that have the potential to enhance the neurogenic capacity in the 
brain through astrocytic activation, which is morphologically characterized by hypertrophy of 
astrocytic somata, processes and prominent expression of GFAP.32-34 Also, VEGF and its 
receptors are expressed in astrocytes themselves and the level of intrinsic VEGF is upregulated 
upon astrocytic activation.35 As a last step, we therefore investigated direct effects of local growth 
factor supplementation on astrocytes below the EMS. Here, GFAP immunofluorescence 
suggested an increased astrocytic activation in the cortical region below the EMS after PDGF- 
and VIP-myoblast implantation. Particularly in animals that received a balanced co-delivery of 
hPDGF-BB and VEGF164, activated astrocytes were in direct contact with CD31-positive 
parenchymal vessels and showed significant VEGF co-localization, possibly due to increased 
intrinsic VEGF mobilization upon astrocytic activation (Figure 6A and 6B). X-gal staining, rtPCR 
and Western blot analysis confirmed positive reporter gene expression, gene product 
transcription and increased VEGF and/or hPDGF-BB levels at the muscle / brain interface of the 
EMS on day 42 (Figure 6C and 6D). Next to increased astrocytic activation, we found a marked 
elevation of phospho-PDGF-R signal intensity in the cortical region of the EMS together with a 
significantly higher co-localization of phospho-PDGF-R and the GFAP-positive surface area 
(Figure 7). 
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DISCUSSION
In the present model of chronic cerebral ischemia and EMS, co-delivery of VEGF and PDGF-BB 
led to superior EMS collateralization and hemodynamic rescue with increased ischemic protection 
compared to delivery of VEGF or PDGF-BB alone. Improved vascular maturity was a key factor 
associated with these beneficial effects. Further, our findings suggest that PDGF-BB-mediated 
astrocytic activation might serve as a secondary neuroprotective mechanism independent from 
therapeutic collateralization.
Growth factor expression and myoblast engraftment
VEGF is a critical mediator of cerebral collateral development and maintenance in the adult 
mouse brain.13,14,16,29 However, VEGF-induced neovascularization requires increased levels of 
VEGF to achieve beneficial effects, yet high VEGF expression levels readily lead to a loss of 
safety. In the present study, VEGF164 alone was delivered at its most optimal microenvironmental 
dose by a monoclonal myoblast population homogeneously expressing the most therapeutic 
amount of VEGF164, as determined previously.17,18 In comparison, co-delivery of VEGF164 and 
hPDGF-BB at a fixed ratio was enacted without any kind of dose control. This co-expression 
through the VIP construct previously enabled robust VEGF delivery and further expanded the 
functional efficacy of VEGF alone.25 Regarding engraftment, we were able to confirm stable fusion 
and gene product expression of all implanted myoblast populations within the temporalis muscle 
of the EMS. The different transcription levels that we observed within the muscle and at the 
muscle / brain interface are likely associated with the fact that PDGF and VIP myoblasts tend to 
engraft better than the remaining myoblast populations due to the trophic effects of hPDGF-BB 
on the myoblasts themselves. Interestingly, in some cases PDGF myoblasts resulted in local 
tumor development within the temporalis muscle, as indicated in Figure 1A. Most likely, this is 
caused by excessive hPDGF-BB expression by some of the myoblasts in the polyclonal 
population due to random differences in copy number and genomic integration sites of the 
retroviral vector. The blush β-gal signal instead of a fiber structure indicates that such tumors are 
not formed exclusively by the myoblasts, which actually encounter an unfavorable environment 
for differentiation and remain as single cells.
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Hemodynamic rescue, transpial collateralization and ischemic neuroprotection
In clinical practice, the degree of cerebrovascular reactivity remains the most important parameter 
to assess the patients’ risk of hemodynamic ischemic stroke, because non-ischemic cerebral 
hypoperfusion is typically characterized by a normal or at best only mild reduction of baseline 
(resting) perfusion.2 Therefore, we first addressed whether VEGF164 and hPDGF-BB co-
expression at the muscle/brain interface of an EMS translated into improved cerebral 
hemodynamics. In this regard, only VIP-treated animals experienced nearly complete 
hemodynamic rescue, whereas the CVRC in animals treated with EV, VEGF or PDGF myoblasts 
alone remained 30-15% below the CVRC response of the non-occluded hemisphere. The time 
line of this hemodynamic rescue was in line with our present and previous results regarding the 
time points of myoblast host integration, collateral outgrowth and vascular remodeling.17,18,23,29 
Importantly, the improved hemodynamics following VIP treatment were not accompanied by an 
overshooting CVRC response or perfusion increase, which is essential to avoid critical 
postoperative hyperperfusion in hemodynamically compromised patients undergoing surgical 
revascularization.36
The main goal of an EMS is the reduction of subsequent ischemic events through 
improvement of collateral flow at the level of the leptomeningeal vasculature, which is a major 
determinant in the severity of stroke.37 Therefore, we next tested whether our hemodynamic 
findings also translated into improved collateralization and regional ischemic protection: Indeed, 
only treatment with VIP myoblasts resulted in a significant and sustained 38% reduction of cortical 
infarct volume after proximal MCA-O, together with a significantly greater number of patent 
transpial collaterals. For the first time, we were also able to show a direct link between the size of 
cortical infarction, the degree of transpial collateralization and the degree of hemodynamic CVRC 
impairment, which correlated not only with the percentage of cortical infarction but also with the 
number of transpial collaterals. The reason for focusing on cortical instead of subcortical infarction 
is the variable degree of native basal and leptomeningeal collateralization in C57BL/6 mice, which 
results in highly variable subcortical stroke volumes after MCA filament occlusion.38,39 In the 
setting of chronic cerebral ischemia, we were able to confirm our previous findings that an 
experimental EMS mainly provides ischemic protection in the cortical territories surrounding the 
newly formed transpial collaterals.29 Since the proportional volume of the cerebral cortex is much 
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smaller than that of the subcortical region, however, additional analysis of the subcortical stroke 
volume in our model would mask the protective effect of the EMS. On the other hand, a distal 
MCA-O model with only a localized focal cortical stroke was not feasible due to the adhesive 
EMS, which limits access to the leptomeningeal cerebral vasculature without injuring the transpial 
collaterals. This relationship between improved EMS collateralization and greater ischemic 
protection is verified by the sustained cortical perfusion across the EMS during MCA-O and in 
line with our observed neuroprotection under myoblast-mediated co-delivery of VEGF164 and 
hPDGF-BB.
Vascular maturation and pericyte recruitment
While VEGF is the crucial factor to promote endothelial cell growth, PDGF-BB is essential for 
stabilization of blood vessels by recruiting pericytes for regulation of vessel diameters and blood 
flow.20,21 However, VEGF may also act as a negative regulator of pericyte function and vessel 
maturation,19 which is suggested by the fact that VEGF164 alone failed to sustain pericyte 
recruitment around parenchymal microvessels or transpial collaterals. In comparison, treatment 
with VEGF164 and hPDGF-BB co-expressing VIP myoblasts not only resulted in improved 
hemodynamic rescue, transpial collateralization and ischemic protection, but also in a higher pro-
angiogenic activity with significantly improved pericyte recruitment as a sign of greater vascular 
maturation. Remarkably, this increased pericyte recruitment was also noted around the newly 
formed transpial EMS collaterals and paralleled by an activation of PDGF receptor beta (PDGF-
Rβ) (Supplemental Figure II), which may have relevant clinical implications, because autopsy 
reports in patients that underwent an EMS demonstrated that the transpial EMS collaterals appear 
to have a fragile structure with a thin and sparse media composed mainly of smooth muscle actins 
without a mature perivascular network.40 Also, we cannot exclude that an increased microvascular 
smooth muscle cell coverage and subcortical capillary arterialization, where remodeled capillaries 
function as collaterals to hypoperfused tissue, may have contributed to the hemodynamic rescue 
and ischemic protection that we noted.13,14,31,41
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Direct effect and limitations of localized hPDGF-BB delivery
The sporadic tumor formation following implantation of polyclonal PDGF myoblasts requires a 
discussion of safety implications and their possible solutions: As stated, hPDGF-BB production 
by polyclonal PDGF myoblasts was almost 5-fold higher than that of VIP myoblasts, which 
explains why tumors were not observed in the VIP-treated animals. Further, our work provides 
proof-of-principle of the superiority of the combination delivery over VEGF delivery alone, even if 
VEGF is delivered in its most optimal, homogeneous dose by the monoclonal population 
employed here. However, refinements need to be enacted for therapeutic application, such as 
rapid FACS purification to exclude cells expressing excessive PDGF-BB doses, which can easily 
be performed based on the intensity of the CD8 marker, as described previously.42 The sporadic 
tumor formation following hPDGF-BB supplementation also explains another surprising 
observation: In contrast to what might have been expected, we noted a similar hemodynamic 
recovery following hPDGF-BB supplementation and supplementation of VEGF164 alone, which 
could be due to the high amount of VEGF protein also in hPDGF-BB treated groups. This 
anomalous amount of VEGF protein in tissue treated with PDGF myoblasts is most likely 
endogenous and upregulated due to tumor formation with ensuing hypoxia, which functionally 
causes the tissue treated with PDGF myoblasts to behave like tissue under VEGF conditions. 
Nevertheless, co-delivery of VEGF164 and hPDGF-BB in VIP myoblasts still remained superior, 
because the expression of both factors is balanced and coordinated through the bi-cistronic VIP 
vector in every cell, whereas in hPDGF-BB-induced tumors, both factors are expressed 
heterogeneously throughout the tissue. Although we did not find significant differences of the 
endogenous VEGF164 expression within the temporalis muscle, transcription of endogenous 
VEGF164 at the muscle/brain interface was significantly upregulated in VIP animals as sign of the 
increased pro-angiogenic activity in this group. Interestingly, we also noted a trend towards a 
higher endogenous VEGF164 transcription in animals that received hPDGF-BB alone, which is in 
line with our hypothesis of tumor-ensuing hypoxia as a cause for the increased VEGF164 protein 
levels in these animals (Supplemental Figure III).
Interestingly, myoblast mediated growth factor supplementation also resulted in an 
increased activation of astrocytes and co-localization of VEGF within astrocytes / astrocytic 
processes and endothelial cells in the cortical parenchyma below the EMS (Figure 6 and 
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Supplemental Figure IV). The significantly increased PDGF-Rβ expression on reactive astrocytes 
particularly in PDGF-treated animals (Figure 7) suggests that the observed astrocytic activation 
appears to be a direct effect following PDGF-BB delivery, which is in line with our reporter-gene 
expression analysis and molecular findings at the muscle / brain interface of the EMS but also 
with previous results, demonstrating a PDGF-BB-dependent astrocytic activation and pro-
inflammatory response with monocyte recruitment via induction of monocyte chemoattractant 
protein 1 (MCP-1) and downstream activation of nuclear factor κB (NFκB).17,18,23,29 Possibly, this 
astrocytic activation could be a second reason for favorable hemodynamic recovery, because 
activation of NFκB with stabilization of hypoxia-inducible factor (HIF)-1α expression has been 
identified as a key pathway for capillary arterialization and maturation of a new arterial collateral 
network following shear-stress induced endothelial activation of collateral outgrowth.16 Further, 
astrocytic activation could also have contributed to direct neuroprotection by reduction of reactive 
oxidant species and activation of antioxidant mechanisms within activated astrocytes43 next to an 
increased intrinsic VEGF mobilization, which was shown to directly contribute to structural 
neuroprotection with improved functional recovery following acute ischemic stroke.44,45 Apart from 
extracellular secretion, the pattern and shape of VEGF localization in GFAP- and CD31-negative 
areas could be an expression of nuclear and perinuclear VEGF accumulation in neuronal or peri-
arteriole smooth muscle cells following the increase of HIF-1α expression as an adaptive change 
underlying a low oxygen environment in chronic hypoxia.46,47
Study design limitations
The use of only young, healthy, male animals requires explanation, because in preclinical stroke 
research internal and external validity must be reduced by limiting bias and including aged, co-
morbid animals of both sexes. However, our present study was an exploratory proof-of-concept 
investigation with focus on a novel approach for therapeutic cerebral collateralization in a model 
of cerebral hypoperfusion, which we previously established in male C57BL/6N mice.31 
Importantly, the degree of chronic cerebral ischemia above the threshold of ischemic stroke in 
mice is largely influenced by the native cerebral collateral vasculature, which underlies a high 
developmental variability and influences the degree of hemodynamic impairment.31,38 Further, 
differences in molecular mechanisms of ischemic cell death and stroke outcome have been 
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observed in males and females. This difference is usually assigned to the estrus cycle in female 
mice, because estrogen has been shown to protect the brain in numerous models of experimental 
brain injury. For the purpose of standardization, we therefore deliberately matched age, sex, and 
genetic background of our animals according to our previously established model29,31 and 
designed our experiments according to the initial Stroke Therapy Academic Industry Roundtable 
(STAIR) recommendations, where such exploratory studies are recommended to be performed 
in young, healthy animals without vascular disease or vascular risk factors.48 Thus, to what extent 
the present approach would be beneficial if one of the driving risk factors for stroke and stroke 
outcomes were present still needs to be determined.
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B IRES rtPCR - muscle VEGF/PDGF Western blot - muscle
Day 42
β-gal 
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c
PDGF VIP
*
Myoblast engraftment and gene-product expression
(A) Immunohistochemical X-gal staining confirms stable engraftment of EV, VEGF, PDGF and VIP myoblasts on 
day 21 after implantation into the temporalis muscle. The asterisk within the area of blush reporter gene 
expression exemplifies a local tumor formation after implantation of myoblasts expressing hPDGF-BB alone. Bar = 
200µm; m = muscle, c = cortex; dashed line = muscle / brain interface. (B) Real-time PCR using IRES primer and 
Western blot confirm exogenous gene product transcription and protein expression within the temporalis muscle 
on day 42 after myoblast implantation; *p<0.05. The panels on the right show the normalized integrated densities 
corresponding to the Western Blot bands for VEGF and PDGF-BB.
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Figure 2
A
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R
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2000
Hemodynamic rescue following VEGF164 and hPDGF-BB co-delivery
(A) Real-time laser speckle images of cortical perfusion before (left) and after (right) acetazolamide showing 
the improved hemodynamic response in VIP-treated animals on day 42. The dashed rectangle shows the 
area of perfusion assessment. R = right. (B) Line graphs illustrating the mean resting (baseline) perfusion 
(CBF-Flux; upper panel) and mean cerebrovascular reserve capacity (CVRC expressed as the percent 
change in CBF-Flux; lower panel) in animals treated with EV, VEGF, PDGF or VIP myoblasts over the 84-
day monitoring period. Although baseline perfusion (upper panel) remained stable during the monitoring 
period, statistical differences compared to day 0 were found on days 7, 21 and 84 in VIP-treated animals 
and on day 84 in animals that received PDGF myoblasts (*p<0.05 versus day 0 for VIP and PDGF). 
Regarding hemodynamic recovery, however, VIP resulted in superior hemodynamic rescue compared to 
day 0 beginning at day 21 (*p<0.05), next to significant CVRC improvement on day 42 compared to empty 
vector (EV) myoblasts (#p<0.05 for VIP versus EV). To a lesser extent, hemodynamic rescue compared to 
day 0 was also noted in VEGF and PDGF-treated animals (*p<0.05 compared to day 0 for VEGF and 
PDGF). The dashed horizontal lines illustrate the normalized resting perfusion (100%) and mean CVRC 
(42%) of the non-occluded hemispheres on day 0.
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Figure 3 
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*p = 0.016 
Cortical stroke and regional perfusion following MCA-O 
(A) T2-weighted MR (left) and Laser Speckle (right) images 
illustrate differences in T2 signal hyperintensity (defined as 
infarction) and perfusion after ipsilateral MCA-O on day 42 
in animals treated with EV (upper panels) and VIP (lower 
panels) myoblasts. R = right. (B) Bar graph illustrating the 
percentage of cortical infarction (*p<0.05) determined in 
MR imaging and correlation analysis confirming the 
significant association between the size of the infarction 
and the degree of hemodynamic impairment in VIP-treated 
animals (*p=0.016; r = -0.59).  
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Figure 4 
Neuronal cells after MCA-O 
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VIP PDGF 
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NeuN FITC NeuN FITC 
VEGF 
Neuroprotection after MCA-O and transpial collateralization 
(A) Photomicrographs of the muscle / brain interface after MCA-O and FITC-lectin perfusion on day 42 
illustrate the higher number of surviving neuronal cells post stroke together with the increased EMS 
collateralization measured as the number of transpial collaterals in VIP-treated animals. Bar = 100µm. (B) 
Bar graph illustrating the number of NeuN positive cells in the cortical region below the EMS (*p<0.05) and 
(C) showing the corresponding number of transpial collaterals (left) and the EMS take-rate (right) 
determined by FITC-lectin perfusion through the external carotid artery feeding the EMS after ipsilateral 
MCA-O; *p<0.05. (D) Correlation analysis between the degree of hemodynamic impairment and the 
number of transpial collaterals on day 42 (**p=0.0076; r = 0.29). The bar graph illustrates the CVRC 
depending on the number of collaterals; *p<0.05. 
Collateral number and EMS take rate 
+ 
- 
Day 42 
**p = 0.0076 
> 10 
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Vessel density and pericyte recruitment 
(A) Photomicrographs of the cortical region below the EMS on day 42 show the increased CD31-positive 
signal and CD31 / Desmin co-localization following EMS and implantation of VIP myoblasts. Bar = 100µm. 
(B) Bar graphs of the microvascular density (1/mm2) and vascular pericyte coverage (%) in vessels < 
10µm (upper graphs) and > 10µm (right); *p<0.05. (C) High-power magnification photomicrographs of the 
muscle/brain interface obtained with confocal imaging in animals that underwent FITC-lectin perfusion for 
visualization of transpial collaterals in combination with CD31 / Desmin staining illustrate the increased 
pericyte recruitment around patent transpial collaterals as a distinct peri-collateral Desmin-positive signal 
in animals that received VIP. The dashed rectangle illustrates the area of detail enlargement. Bar = 
100µm. (D) Bar graph quantifying the pericyte coverage of transpial collaterals; *p<0.05.   
VEGF CD31 FITC Desmin VIP CD31 FITC Desmin 
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Astrocyte activation and intrinsic VEGF mobilization 
(A) Photomicrographs of the cortical region below the EMS and of an untreated hemisphere on day 42 show 
increased GFAP-positive astrocytic activation in animals receiving PDGF or VIP myoblasts with GFAP / VEGF co-
localization (arrows) as a sign of intrinsic VEGF mobilization in VIP-treated animals. The dashed rectangle 
identifies the area of detail enlargement on the right. Bar = 100µm. (B) Bar graph quantifying the area (µm2) of 
GFAP / VEGF co-localization per mm2; *p<0.05. (C) Reporter gene expression at the muscle / brain interface 
(arrows) and (D) real-time PCR using IRES primer and Western blot confirm exogenous gene product 
transcription and protein expression at the muscle / brain interface on day 42 after myoblast implantation; 
*p<0.05. m = muscle; c = cortex. 
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Figure 7
Figure 7: Phospho-PDGF-Rβ / GFAP co-localization in the cortical region below the EMS
(A) Photomicrographs of the cortical region below the EMS on day 42 show an increased GFAP-positive signal in 
animals receiving VEGF, PDGF or VIP myoblasts together with marked phospho-PDGF-Rβ expression. Bar = 
100µm. (B) High-power magnification showing astrocytic GFAP / phospho-PDGF-Rβ co-localization. Bar = 50µm. 
(C) Quantification of the percent phospho-PDGF-Rβ-coverage of the GFAP-positive surface area; *p<0.05.
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